Share-based Payment Arrangement, Expense of Aura Biosciences, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aura Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Aura Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,688,000, a 34% increase year-over-year.
  • Aura Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $13,972,000, a 23% increase year-over-year.
  • Aura Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $11,722,000, a 34% increase from 2023.
  • Aura Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,772,000, a 37% increase from 2022.
  • Aura Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6,412,000, a 178% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aura Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $13,972,000 $3,688,000 +$938,000 +34% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $13,034,000 $3,833,000 +$707,000 +23% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $12,327,000 $3,514,000 +$605,000 +21% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $11,722,000 $2,937,000 +$334,000 +13% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $11,388,000 $2,750,000 +$425,000 +18% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $10,963,000 $3,126,000 +$1,195,000 +62% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $9,768,000 $2,909,000 +$996,000 +52% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $8,772,000 $2,603,000 +$784,000 +43% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $7,988,000 $2,325,000 +$613,000 +36% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $7,375,000 $1,931,000 +$644,000 +50% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $6,731,000 $1,913,000 +$319,000 +20% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $6,412,000 $1,819,000 +$522,000 +40% 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $5,890,000 $1,712,000 +$1,158,000 +209% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $4,732,000 $1,287,000 +$1,016,000 +375% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $3,716,000 $1,594,000 +$1,409,000 +762% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $2,307,000 $1,297,000 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q3 2021 $554,000 +$363,000 +190% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $271,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $185,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $191,000 01 Jul 2020 30 Sep 2020 10-Q 24 Nov 2021 2021 Q3

Aura Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $11,722,000 +$2,950,000 +34% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $8,772,000 +$2,360,000 +37% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $6,412,000 +$4,105,000 +178% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $2,307,000 +$1,571,000 +213% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $736,000 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.